PCSK9 and familial hyperaldosteronism: In Novosibirsk, mutation screening of patients with hypercholesterolemia is currently conducted by targeted sequencing of several genes involved in the development of monogenic FH (i.e., LDLR, APOB, PCSK9, and LDLRAP1).